Shuzhi Lin
Overview
Explore the profile of Shuzhi Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu X, Lin S, Liu W, Liu Q, Yin L, Feng B
Front Public Health
. 2025 Mar;
13:1500603.
PMID: 40066008
Background: The high-quality development of the traditional Chinese medicine (TCM) industry is dependent on supportive policies and requires higher levels of coordination and integration. National and local government policies must...
2.
Liu W, Ren B, Zhu X, Lin S, Lei S, Feng B
Geriatr Nurs
. 2024 Nov;
61:34-40.
PMID: 39541630
Aims: We aimed to investigate the status quo of self-management knowledge, attitudes, and behaviors (KAB) among patients with type 2 diabetes mellitus (T2DM) in community health service centers. Methods: We...
3.
Liu W, Lin S, Zhu X, Yin L, Liu Q, Lei S, et al.
Front Immunol
. 2024 Sep;
15:1433075.
PMID: 39290710
Background: On April 18, 2024, the U.S. Food and Drug Administration officially required updating of the "boxed warning" for T cell malignancies for all chimeric antigen receptor T cell (CAR-T)...
4.
Lin S, Lei S, Liu W, Zhu X, Yin L, Liu Q, et al.
Int J Clin Pharm
. 2024 May;
46(5):1076-1090.
PMID: 38727779
Background: Establishing effective pharmacovigilance systems globally is challenging due to the need for comprehensive epidemiological data on pharmacovigilance-related events, particularly in countries at different stages of development. Aim: This study...
5.
Zhu X, Ren B, Liu W, Lei S, Lin S, Liu Q, et al.
Public Health
. 2024 Mar;
230:96-104.
PMID: 38521030
Objectives: The popularity of contracted family doctor services in China has been growing in recent years, but community-family-doctor-based type 2 diabetes mellitus (T2DM) intervention programs have yet to be adequately...
6.
Lin S, Lei S, Liu W, Zhu X, Ren B, Feng B
Eur J Clin Pharmacol
. 2023 Dec;
80(2):249-259.
PMID: 38099939
Objectives: To explore the characteristics of the occurrence of antineoplastic drug adverse reactions (ADRs) in breast cancer and to utilize a computerized tool to identify early warning indicators of potentially...
7.
Lei S, Wang N, Ren B, Lin S, Feng B
Expert Opin Drug Saf
. 2023 Mar;
23(1):99-105.
PMID: 36929779
Background: China has the highest proportion of lung cancer-related deaths. Drug therapy is the main tool of comprehensive anticancer treatment. However, most studies to date have focused on certain types...
8.
Lin S, Wang N, Ren B, Lei S, Feng B
Int J Environ Res Public Health
. 2022 Dec;
19(23).
PMID: 36497503
It is crucial to investigate the risk factors inherent in the medication process for cancer patients since improper antineoplastic drug use frequently has serious consequences. As a result, the Severity,...
9.
Ren B, Wang N, Lei S, Lin S, Chen Y, Liu L, et al.
BMJ Open
. 2022 Jul;
12(7):e058670.
PMID: 35840300
Introduction: The management of diabetes has become a critical public health issue in China. The development of community-based type 2 diabetes management in China has not yet reached an ideal...
10.
Wang N, Ren B, You H, Chen Y, Lin S, Lei S, et al.
Health Expect
. 2022 Jan;
25(2):791-801.
PMID: 34989054
Objectives: We aimed to explore the current status of medication adherence, safety awareness and practice among patients with lung cancer. Methods: We conducted a questionnaire-guided cross-sectional study in Xi'an, Yulin,...